var data={"title":"Vinorelbine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vinorelbine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7154?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vinorelbine-drug-information\" class=\"drug drug_general\">see &quot;Vinorelbine: Drug information&quot;</a> and <a href=\"topic.htm?path=vinorelbine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vinorelbine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708855\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Vinorelbine tartrate injection should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Not for intrathecal use: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">This product is for intravenous (IV) use only. Intrathecal administration of other vinca alkaloids has resulted in death. Syringes containing this product should be labeled &ldquo;Warning &mdash; for IV use only. Fatal if given intrathecally.&rdquo;</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Severe granulocytopenia resulting in increased susceptibility to infection may occur. Granulocyte counts should be greater than or equal to 1000 cells/mm<sup>3</sup> prior to the administration of vinorelbine tartrate. The dosage should be adjusted according to complete blood counts with differentials obtained on the day of treatment.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Extravasation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">It is extremely important that the IV's needle or catheter be properly positioned before vinorelbine tartrate is injected. Administration of vinorelbine tartrate may result in extravasation causing local tissue necrosis or thrombophlebitis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234356\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Navelbine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234357\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Navelbine;</li>\n      <li>Vinorelbine Injection, USP;</li>\n      <li>Vinorelbine Tartrate for Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042325\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimicrotubular</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Vinca Alkaloid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042360\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vinorelbine-drug-information\" class=\"drug drug_general\">see &quot;Vinorelbine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hodgkin&rsquo;s lymphoma; refractory or recurrent:</b> Limited data available: IV: Children &ge;10 years and Adolescents: 25 mg/m<sup>2</sup> once weekly on days 1 and 8 of a 21-day cycle in combination with gemcitabine (Cole, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leukemias; acute (ALL, AML), refractory, or recurrent:</b> Limited data available: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 0.67 mg/<b>kg</b> once weekly on days 0, 7, 14 of a 14-day cycle in combination with topotecan, clofarabine, and thiotepa (TVTC regimen) (Steinherz, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: 20 mg/m<sup>2</sup> once weekly on days 0, 7, and 14 of a 14-day cycle in combination with topotecan, clofarabine, and thiotepa (TVTC regimen) (Shuka, 2014; Steinherz, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Solid tumors; refractory or recurrent:</b> Limited data available: Children and Adolescents: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Monotherapy:</i> 30 mg/m<sup>2</sup> once weekly for weeks 1-6 of an 8-week cycle for 10 courses; may reduce dosage to 27 mg/m<sup>2</sup> for Grade 3 or 4 hematologic toxicity in patients who demonstrate objective response or who have had treatment delay beyond 63 days (week 9) from the previous course (Kuttesch, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Combination therapy:</i> 25 mg/m<sup>2</sup> once weekly for 3 weeks on days 1, 8, and 15 of each 28-day cycle in combination with cyclophosphamide (Casanova, 2004; Minard-Colin, 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: <b>Non-small cell lung cancer (NSCLC):</b> IV: <b>Note:</b> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Monotherapy:</i> 30 mg/m<sup>2</sup> every 7 days until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy:</i> 25-30 mg/m<sup>2</sup> every 7 days in combination with cisplatin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hematological toxicity:</b> Adults: <b>Note:</b> In patients with concurrent hematologic toxicity and hepatic impairment, administer the lower of the doses determined from the adjustment recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Granulocyte counts should be &ge;1000 cells/mm<sup>3</sup> prior to the administration of vinorelbine. Adjustments in the dosage of vinorelbine should be based on granulocyte counts obtained on the day of treatment as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Granulocytes &ge;1500 cells/mm<sup>3</sup> on day of treatment: Administer 100% of starting dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Granulocytes 1000-1499 cells/mm<sup>3</sup> on day of treatment: Administer 50% of starting dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Granulocytes &lt;1000 cells/mm<sup>3</sup> on day of treatment: Do not administer. Repeat granulocyte count in 1 week; if 3 consecutive doses are held because granulocyte count is &lt;1000 cells/mm<sup>3</sup>, discontinue vinorelbine. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For patients who, during treatment, have experienced fever and/or sepsis while granulocytopenic or had 2 consecutive weekly doses held due to granulocytopenia, subsequent doses of vinorelbine should be: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">75% of starting dose for granulocytes &ge;1500 cells/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">37.5% of starting dose for granulocytes 1000-1499 cells/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for neurotoxicity:</b> Adults: Neurotoxicity &ge;grade 2: Discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for other adverse events:</b> Adults: Severe adverse events: Reduce dose or discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal insufficiency: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Initial: IV: Reduce dose to 20 mg/m<sup>2</sup>/week; administer either after dialysis (on dialysis days) or on nondialysis days (Janus, 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: <b>Note:</b> In patients with concurrent hematologic toxicity and hepatic impairment, administer the lower of the doses determined from the adjustment recommendations. Administer with caution in patients with hepatic insufficiency. In patients who develop hyperbilirubinemia during treatment with vinorelbine, the dose should be adjusted for total bilirubin as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum bilirubin &le;2 mg/dL: Administer 100% of dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum bilirubin 2.1-3 mg/dL: Administer 50% of dose (Ecklund, 2005; Floyd, 2006; Superfin, 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum bilirubin &gt;3 mg/dL: Administer 25% of dose (Ecklund, 2005; Floyd, 2006; Superfin, 2006) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234335\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Navelbine: 10 mg/mL (1 mL); 50 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (1 mL); 50 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (1 mL); 50 mg/5 mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234320\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042366\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: <b>For IV use only; FATAL IF GIVEN INTRATHECALLY.</b> Administer as a direct intravenous push or rapid bolus, over 6 to 10 minutes (up to 30 minutes); in pediatric trials, vinorelbine typically administered over 6 to 10 minutes. Longer infusions may increase the risk of pain and phlebitis. Intravenous doses should be followed by at least 75 to 125 mL of NS or D<sub>5</sub>W to reduce the incidence of phlebitis and inflammation. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vesicant; avoid extravasation. Assure proper needle or catheter position prior to administration. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (See Management of Drug Extravasations for more details); apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (P&eacute;rez Fidalgo 2012). Remaining portion of the vinorelbine dose should be infused through a separate vein. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132725\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234350\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Intact vials are stable at room temperature of 25&deg;C (77&deg;F) for up to 72 hours. Solutions diluted for infusion in polypropylene syringes (D5W or NS) or polyvinyl chloride bags (D5W, NS, <sup>1</sup>/<sub>2</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS, LR, or Ringer's) are stable for 24 hours at 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F). After preparation, keep vinorelbine in a location <b>away</b> from the separate storage location recommended for intrathecal medications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042326\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of non-small cell lung cancer (FDA approved in adults); has also been used for refractory/recurrent solid tumors, Hodgkin&rsquo;s lymphoma, and leukemias</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234403\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vinorelbine may be confused with vinBLAStine, vinCRIStine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vinorelbine (50 mg/5 mL; Hospira manufacturer) may be confused with conventional cytarabine (100 mg/5 mL; Hospira manufacturer) due to similar packaging; potential for inadvertent intrathecal administration of vinorelbine may occur (ISMP, [Smetzer 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vinorelbine is intended <b>for IV use only</b>: Inadvertent intrathecal administration of other vinca alkaloids has resulted in death. Syringes containing vinorelbine should be labeled <b>&ldquo;For IV use only. Fatal if given intrathecally.&rdquo;</b> Vinorelbine should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep vinorelbine in a location <b>away</b> from the separate storage location recommended for intrathecal medications. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234399\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Reported with single-agent therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, localized phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Decreased deep tendon reflex, fatigue, peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, diarrhea, nausea, paralytic ileus, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, febrile neutropenia, granulocytopenia (nadir: 7 to 10 days; recovery 14 to 21 days), leukopenia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum AST, increased serum bilirubin (total bilirubin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (includes erythema at injection site, vein discoloration), pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, jaw pain, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal pain, anaphylaxis, angioedema, back pain, deep vein thrombosis, dysphagia, esophagitis, flushing, headache, hemolytic-uremic syndrome, hemorrhagic cystitis, hypersensitivity reaction, hypertension, hyponatremia, hypotension, intestinal necrosis, intestinal obstruction, intestinal perforation, interstitial pulmonary disease, ischemic heart disease, localized rash, mucositis, myasthenia, myocardial infarction (rare), pancreatitis, pneumonia, pruritus, pulmonary edema, pulmonary embolism, radiation recall phenomenon (dermatitis, esophagitis), skin blister, SIADH (syndrome of inappropriate antidiuretic hormone secretion), tachycardia, thromboembolism, thrombotic thrombocytopenic purpura, tumor pain, unsteady gait, urticaria, urticaria at injection site, vasodilatation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234341\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Pretreatment granulocyte counts &lt;1000/mm<sup>3</sup></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234324\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Severe granulocytopenia may occur with treatment (may lead to infection); granulocyte counts should be &ge;1000 cells/mm<sup>3</sup> prior to treatment initiation; dosage adjustment may be required based on blood counts (monitor blood counts prior to each dose). </b> Granulocytopenia is a dose-limiting toxicity; nadir is generally 7 to 10 days after administration and recovery occurs within the following 7 to 14 days. Monitor closely for infections and/or fever in patients with severe granulocytopenia. Use with extreme caution in patients with compromised marrow reserve due to prior chemotherapy or radiation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: <b>[US Boxed Warning]: Vesicant; ensure proper catheter or needle position prior to (and during) infusion. Avoid extravasation. Extravasation may cause local tissue necrosis and/or thrombophlebitis.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: May cause severe constipation (grade 3-4), paralytic ileus, intestinal obstruction, necrosis, and/or perforation; some events were fatal. Oral vinorelbine (not available in the US) is associated with a moderate antiemetic potential; antiemetics are recommended to prevent nausea/vomiting (Dupuis 2011; Hesketh 2017; Roila 2016); IV vinorelbine has a minimal emetic potential (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropathy: May cause new-onset or worsening of pre-existing neuropathy; use with caution in patients with neuropathy. Monitor for new or worsening sign/symptoms of neuropathy. Dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Fatal cases of interstitial pulmonary changes and ARDS have been reported with single-agent therapy (mean onset of symptoms: 1 week). Promptly evaluate changes in baseline pulmonary symptoms or any new-onset pulmonary symptoms (eg, dyspnea, cough, hypoxia). Acute shortness of breath and severe bronchospasm have been reported with vinca alkaloids, usually when used in combination with mitomycin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Vinorelbine elimination is predominantly hepatic. While there is no evidence that toxicity is enhanced in patients with elevated transaminases, use with caution in patients with severe hepatic injury or impairment; dosage modification required for elevated total bilirubin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation therapy: May have radiosensitizing effects with prior or concurrent radiation therapy; radiation recall reactions may occur in patients who have received prior radiation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hazardous agent: Avoid eye contamination (exposure may cause severe irritation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; NOT for intrathecal use: <b>[US Boxed Warning]: For IV use only; intrathecal administration of other vinca alkaloids has resulted in death. If dispensed in a syringe, should be labeled &ldquo;for intravenous use only - fatal if given intrathecally&quot;.</b> Vinorelbine should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep vinorelbine in a location <b>away</b> from the separate storage location recommended for intrathecal medications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234388\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234329\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=94136&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: May enhance the adverse/toxic effect of Vinorelbine. Specifically, the combination may be associated with a higher risk of granulocytopenia.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Vinorelbine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: May enhance the neutropenic effect of Vinorelbine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues. Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PACLitaxel (Conventional): May enhance the neurotoxic effect of Vinorelbine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PACLitaxel (Protein Bound): May enhance the neurotoxic effect of Vinorelbine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Management: Avoid the concomitant use of posaconazole and vinca alkaloids when possible. If combined, monitor for increased vinca alkaloid toxicities (eg, neurotoxicity, gastrointestinal toxicity).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234331\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5720023\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have demonstrated embryotoxicity, fetotoxicity, decreased fetal weight, and delayed ossification. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during vinorelbine treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042369\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count (prior to each dose, and after treatment), hepatic function tests; monitor for new-onset pulmonary symptoms (or worsening from baseline); monitor for neuropathy (new or worsening symptoms; monitor infusion site; monitor for signs symptoms of constipation/ileus </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234323\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Vinorelbine is a semisynthetic vinca alkaloid which binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vinorelbine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234340\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: binds extensively to human platelets and lymphocytes (80% to 91%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 2 to 17 years: 21.1 &plusmn; 12.2 L/kg (Johansen 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 25 to 40 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 80% to 91% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic, via CYP3A4, to two metabolites, deacetylvinorelbine (active) and vinorelbine N-oxide </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Triphasic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 2 to 17 years: Terminal: 16.5 &plusmn; 9.7 hours (Johansen 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Terminal: 28 to 44 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (46%); urine (18%, 10% to 12% as unchanged drug) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324098\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Navelbine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $36.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (5 mL): $102.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vinorelbine Tartrate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $30.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (5 mL): $108.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234343\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Filcrin (UY);</li>\n      <li>Navelbin (HN);</li>\n      <li>Navelbine (AE, AR, AT, AU, BB, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, GY, ID, IE, IL, IQ, IR, IS, IT, JM, JO, KR, KW, LB, LT, LU, LY, MT, MX, MY, NL, NO, NZ, OM, PH, PK, PL, QA, RO, RU, SA, SE, SI, SK, SR, SY, TH, TR, TT, TW, VN, YE);</li>\n      <li>Navildez (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Navirel (UA);</li>\n      <li>Neoben (UA);</li>\n      <li>Viessia (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vilne (EC);</li>\n      <li>Vinbine (IN);</li>\n      <li>Vinelbine (ZW);</li>\n      <li>Vinorel (BD);</li>\n      <li>Vinorelsin (ID);</li>\n      <li>Vinorgen (PE, PY);</li>\n      <li>Vinotec (LK);</li>\n      <li>Vinotel (PH);</li>\n      <li>Zinavin (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Casanova M, Ferrari A, Bisogno G, et al, &ldquo;Vinorelbine and Low-Dose Cyclophosphamide in the Treatment of Pediatric Sarcomas: Pilot Study for the Upcoming European Rhabdomyosarcoma Protocol,&rdquo; <i>Cancer</i>, 2004, 101(7):1664-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/15378498/pubmed\" target=\"_blank\" id=\"15378498\">15378498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casanova M, Ferrari A, Spreafico F, et al, &ldquo;Vinorelbine in Previously Treated Advanced Childhood Sarcomas: Evidence of Activity in Rhabdomyosarcoma,&rdquo; <i>Cancer</i>, 2002, 94(12):3263-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/12115359/pubmed\" target=\"_blank\" id=\"12115359\">12115359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cole PD, Schwartz CL, Drachtman RA, et al. Phase II study of weekly gemcitabine and vinorelbine for children with recuurent or refractory Hodgkin&rsquo;s Disease: a children&rsquo;s oncology group report. <i>J Clin Oncol</i>. 2009;27(9):1456-1461.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/19224841/pubmed\" target=\"_blank\" id=\"19224841\">19224841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ecklund JW, Trifilio S, and Mulcahy MF, &ldquo;Chemotherapy Dosing in the Setting of Liver Dysfunction,&rdquo; <i>Oncology (Williston Park)</i>, 2005, 19(8):1057-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/16131047/pubmed\" target=\"_blank\" id=\"16131047\">16131047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. <i>Semin Oncol</i>. 2006;33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JO, Polovich M, McNiff KK, et al, &ldquo;American Society of Clinical Oncology/ Oncology Nursing Society Chemotherapy Administration Safety Standards,&rdquo; <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/19786650/pubmed\" target=\"_blank\" id=\"19786650\">19786650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo; <i>Ann Oncol</i>, 2010, 21(7):1395-403. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johansen J, Kuttesch J, Bleyer WA, et al. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the children&rsquo;s oncology group. <i>Clin Cancer Res</i>. 2006;12(2):516-522. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/16428494/pubmed\" target=\"_blank\" id=\"16428494\">16428494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuttesch JF, Krailo MD, Madden T, et al. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a children&rsquo;s oncology group study. <i>Pediatr Blood Cancer</i>. 2009;53(4):590-593. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/19533657/pubmed\" target=\"_blank\" id=\"19533657\">19533657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LeVeque D and Jehl F, &ldquo;Clinical Pharmacokinetics of Vinorelbine,&rdquo; <i>Clin Pharmacokinet</i>, 1996, 31(3):184-97. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/8877249/pubmed\" target=\"_blank\" id=\"8877249\">8877249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minard-Colin V, Ichante JL, Nguyen L, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma &ndash; a report from the Soci&eacute;t&eacute; Fran&ccedil;aise des Cancers et leuc&eacute;mies de l&rsquo;Enfant et de l&rsquo;adolescent (SFCE). <i>Eur J Cancer</i>. 2012;48:2409-2416.  <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/22633624/pubmed\" target=\"_blank\" id=\"22633624\">22633624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Navelbine (vinorelbine tartrate) [prescribing information]. Parsippany, NJ: Pierre Fabre M&eacute;dicament; October 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo; <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polovich M, Whitford JN and Olsen M, <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schulmeister L, &quot;Extravasation Management: Clinical Update,&quot; <i>Semin Oncol Nurs</i>, 2011, 27(1):82-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/21255716/pubmed\" target=\"_blank\" id=\"21255716\">21255716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shukla N, Kobos R, Renaud T, et al. Phase II trial of clofarabine with topotecan, vinorelbine and thiotepa for pediatric patients with relapsed or refractory acute leukemia. <i>Pediatr Blood Cancer</i>. 2014;61:431-435. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/24115731/pubmed\" target=\"_blank\" id=\"24115731\">24115731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steinherz PG, Shukla N, Kobos R, et al. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa and vinorelbine for patients with relapsed or refractory leukemia. <i>Pediatr Blood Cancer</i>. 2010;54:687-693. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/20205253/pubmed\" target=\"_blank\" id=\"20205253\">20205253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Superfin D, Iannucci AA, and Davies AM, &ldquo;Commentary: Oncologic Drugs in Patients With Organ Dysfunction: A Summary,&rdquo; <i>Oncologist</i>, 2007, 12(9):1070-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinorelbine-pediatric-drug-information/abstract-text/17914077/pubmed\" target=\"_blank\" id=\"17914077\">17914077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 94136 Version 108.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708855\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F234356\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F234357\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1042325\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1042360\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F234335\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F234320\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1042366\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132725\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F234350\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1042326\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F234403\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F234399\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F234341\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F234324\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F234388\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F234329\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F234331\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5720023\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1042369\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F234323\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F234340\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324098\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F234343\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/94136|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vinorelbine-drug-information\" class=\"drug drug_general\">Vinorelbine: Drug information</a></li><li><a href=\"topic.htm?path=vinorelbine-patient-drug-information\" class=\"drug drug_patient\">Vinorelbine: Patient drug information</a></li></ul></div></div>","javascript":null}